TELA - TELA Bio, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
14.93
-0.21 (-1.39%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close15.14
Open15.34
Bid14.65 x 1000
Ask14.98 x 900
Day's Range14.66 - 15.92
52 Week Range10.78 - 15.92
Volume60,755
Avg. Volume100,144
Market Cap170.284M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-108.30
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.25
  • GlobeNewswire

    TELA Bio Announces Preliminary Revenue for Fourth Quarter and Full Year 2019

    TELA Bio, Inc. (“TELA”) (TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announces unaudited preliminary revenue for the fourth quarter and full year 2019. The company expects reported revenue for the fourth quarter of 2019 to be $4.7 million to $4.9 million, an increase of 94%-102% compared to $2.4 million in the fourth quarter of 2018. The company expects reported revenue for the full year of 2019 to be $15.3 million to $15.5 million, an increase of 85%-87% compared to $8.3 million for the full year of 2018.

  • GlobeNewswire

    TELA Bio Announces Third Quarter 2019 Financial Results

    Revenue increased 80% year-over-year to $4.0 million Completed initial public offering in November 2019, raising net proceeds of $50.7 million MALVERN, Pa., Dec. 18, 2019 --.

  • GlobeNewswire

    TELA Bio Awarded Contract with HealthTrust Purchasing Group

    MALVERN, Pa., Dec. 06, 2019 -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new.

  • GlobeNewswire

    TELA Bio Appoints Federica O’Brien to Board of Directors

    MALVERN, Pa., Nov. 13, 2019 -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new.

  • GlobeNewswire

    TELA Bio Announces Closing of Initial Public Offering of Common Stock

    MALVERN, Pa., Nov. 13, 2019 -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new.

  • GlobeNewswire

    TELA Bio Announces Pricing of Initial Public Offering of Common Stock

    TELA Bio, Inc. (“TELA”), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the pricing of its initial public offering of 4,000,000 shares of common stock at a public offering price of $13.00 per share, before underwriting discounts and commissions, for gross proceeds of $52.0 million. All shares of common stock are being offered by TELA. TELA has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.